-
EFFECT OF MENTAL HEALTH PARITY AND ADDICTION EQUITY ACT (MHPAEA) ON MENTAL HEALTH CARE UTILIZATION
Mar 18, 2026, 21:38 PM -
COMPARISON OF ISCHEMIC STROKE INCIDENCE RATES IN HUNGARY AND EUROPE BASED ON DATA FROM THE GLOBAL BURDEN OF DISEASE STUDY
Mar 18, 2026, 21:38 PM -
AN AUTOMATED FEASIBILITY ASSESSMENT TOOL FOR INDIRECT TREATMENT COMPARISONS ACROSS MULTIPLE ANALYTICAL METHODS
Mar 18, 2026, 21:38 PM -
HEALTHCARE RESOURCE UTILIZATION FOLLOWING HUMAN METAPNEUMOVIRUS (HMPV) OR RESPIRATORY SYNCYTIAL VIRUS (RSV) DIAGNOSIS IN ADULTS: A RETROSPECTIVE, SELF-CONTROLLED, CLAIMS-BASED STUDY IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
WHEN TRIALS FALL SHORT: LEVERAGING REAL-WORLD EVIDENCE TO ADVANCE PRECISION THERAPIES
Mar 18, 2026, 21:38 PM -
COMPARATIVE ANALYSIS OF NATIONAL HTA DECISIONS IN ANTINEOPLASTIC, IMMUNOMODULATORY, AND NERVOUS SYSTEM THERAPIES ACROSS FOUR EUROPEAN COUNTRIES
Mar 18, 2026, 21:38 PM -
COST OF ILLNESS AMONG ALZHEIMER’S DISEASE AND RELATED DEMENTIAS (ADRD) MEDICARE PATIENTS IN THE UNITED STATES BETWEEN 2011-2021
Mar 18, 2026, 21:38 PM -
A DESCRIPTIVE ANALYSIS OF KEY FINDINGS FROM THE 2025-2026 ISPOR STUDENT INTEREST SURVEY
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS AND EFFICACY OF FIRST-LINE THERAPIES IN PATIENTS WITH MET EXON 14 SKIPPING-MUTATED NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
RISKY BUSINESS: HOW HEALTH PREFERENCE RESEARCH CAPTURES RISK TOLERANCE
Mar 18, 2026, 21:38 PM -
AFFORDABILITY OF NOVEL DISEASE-MODIFYING THERAPIES: TAFAMIDIS AND ATTR-CM
Mar 18, 2026, 21:38 PM -
THE ECONOMIC COST OF PREVENTABLE BLINDNESS: PROJECTING THE SOCIOECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN CHILE (2017-2032)
Mar 18, 2026, 21:38 PM -
THE ACCESSIBILITY OF ANTI-CANCER DRUGS IN CHINA'S URBAN CUSTOMIZED COMMERCIAL MEDICAL INSURANCE
Mar 18, 2026, 21:38 PM -
REAL-WORLD EFFECTIVENESS OF DUPILUMAB IN REDUCING ORAL AND INHALED CORTICOSTEROID USE AMONG US PATIENTS WITH ASTHMA: ANALYSIS FROM THE HEALTHCARE INTEGRATED RESEARCH DATABASE
Mar 18, 2026, 21:38 PM -
OBSERVED CARDIOVASCULAR DISEASE PREVALENCE AMONG OBESE AND TYPE 2 DIABETES PATIENTS WITH AND WITHOUT GLP-1 TREATMENT
Mar 18, 2026, 21:38 PM -
MEASURING PATIENT-REPORTED DERMATOLOGIC SIDE EFFECTS OF CANCER TREATMENT: PSYCHOMETRIC EVALUATION OF THE SKINDEX-16 IN NON-SMALL CELL LUNG CANCER
Mar 18, 2026, 21:38 PM -
MEDICARE COST OF MINIMALLY INVASIVE BIOMARKER TESTS TO DETECT DONOR-DERIVED CELL-FREE DNA (DD-CFDNA)
Mar 18, 2026, 21:38 PM -
REAL-WORLD TREATMENT PATTERNS IN COMMERCIALLY INSURED PATIENTS WITH RECURRENT OR PROGRESSIVE ENDOMETRIAL CANCER (EC) IN THE USA
Mar 18, 2026, 21:38 PM -
POWER, POLITICS, AND PRICE: GOVERNANCE FAILURES IN NEPAL’S PHARMACEUTICAL SYSTEM AND THE UHC CHALLENGE
Mar 18, 2026, 21:38 PM -
THE ECONOMIC BURDEN OF HIV IN MEXICO: A LIFETIME COST-OF-ILLNESS ANALYSIS
Mar 18, 2026, 21:38 PM
